Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Boronic Acids
  • Lymphoma, Mantle-Cell
  • Pyrazines

abstract

  • These results confirm the activity of bortezomib in relapsed or refractory MCL, with predictable and manageable toxicities. Bortezomib provides significant clinical activity in terms of durable and complete responses, and may therefore represent a new treatment option for this population with usually very poor outcome. Studies of bortezomib-based combinations in MCL are ongoing.

publication date

  • October 20, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.07.9665

PubMed ID

  • 17001068

Additional Document Info

start page

  • 4867

end page

  • 74

volume

  • 24

number

  • 30